Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT of FMP30 in Relapsing-Remitting Multiple Sclerosis
NCT03594487Phase 1Terminated
- Start
- Nov 2018
- Primary completion
- Dec 2024
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of FMP-30 in relapsing-remitting multiple sclerosis (RRMS) (2 arms). Primary endpoints: Participants Who Complete the Study Protocol at 48 weeks, Change in Fecal Microbiota at 12 weeks and 2 more. Started Nov 2018; status: terminated.
02
Drugs
FMP-30
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03594487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03594487.